#	Pagina
attuale pagina	/open-h2020/projects/200561/index.html

Opendata, web and dolomites

RITA-MI

Rituximab in Acute Myocardial Infarction

Total Cost €

EC-Contrib. €

Partnership

Views

RITA-MI project word cloud

Explore the words cloud of the RITA-MI project. It provides you a very rough idea of what is the project "RITA-MI" about.

first function efficacy acute heart scheme site instrumental reducing orchestration mature breaking considerable discovery monocytes morbidities ultimate disease drug excess mortality readily co re ground mab lymphocytes monoclonal benefit inflammatory diseases circulating ischemic hypothesis nat series antibody 2013 cells safe forget interestingly infarction successful med substantially 30 25 cv proof dose clinical ineffective mobilisation trial chemokine reduces limit et correspond immune group selective therapy infarct size burden validated grant death therapeutic reduce patients rita followed depletes mi initiation stemi improves cvd rapid intravenous recruitment fire cell risk erc single rituximab injury purposing events cd20 myocardial ccl7 infusion morbidity translate therapies pursued zouggari al cardiovascular starting

Project "RITA-MI" data sheet

The following table provides information about the project.

Coordinator	THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE Organization address address: TRINITY LANE THE OLD SCHOOLS city: CAMBRIDGE postcode: CB2 1TN website: www.cam.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	149˙402 €
EC max contribution	149˙402 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2015-PoC
Funding Scheme	ERC-POC
Starting year	2016
Duration (year-month-day)	from 2016-03-01 to 2018-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE Organization address address: TRINITY LANE THE OLD SCHOOLS city: CAMBRIDGE postcode: CB2 1TN website: www.cam.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	coordinator	15˙266.00
2	PAPWORTH HOSPITAL NHS FOUNDATION TRUST PAPWORTH HOSPITAL NHS FOUNDATION TRUST Organization address address: PAPWORTH EVERARD city: CAMBRIDGE postcode: CB23 3RE website: www.papworthhospital.nhs.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	participant	134˙136.00

Map

Project objective

Cardiovascular diseases (CVD) represent a major cause of morbidity and mortality. The best current therapy reduces CV risk by only 25-30% and remains ineffective in reducing the excess risk associated with several co-morbidities. Therefore, there is considerable need for new therapies to limit the burden of CVD. Based on a current ERC Starting Grant project, the applicant’s group proposed and validated the concept that mature B lymphocytes are instrumental in the orchestration of the inflammatory response after ischemic myocardial injury, in part through production of CCL7 chemokine and mobilisation/recruitment of inflammatory monocytes to the infarction site (Zouggari Y et al., Nat Med 2013). Our goal now is to translate this ground-breaking discovery and novel therapeutic concept into benefit for patients. The overall objective of the RITA-MI project is to develop a new and cost-effective therapy for patients with acute myocardial infarction (MI) based on selective targeting of the B cell immune response, with the ultimate aim to substantially reduce the high risk of death and major cardiovascular events associated with the disease. Interestingly, the drug, CD20 monoclonal antibody (mAb) rituximab, is readily available for testing in a re-purposing scheme, allowing for rapid initiation of this proof-of-concept clinical trial. Working Hypothesis: A single infusion of rituximab at the acute phase of MI is safe, substantially depletes circulating B cells, and has the potential to limit infarction size and improves myocardial heart function. Overall objective: Does a ‘fire and forget’ approach with rituximab (a single intravenous infusion) reduce infarct size and/or improve heart function in patients with acute STEMI? The overall aim will be pursued through a series of specific objectives, which will correspond to a first step of a dose-finding proof-of-concept study (the present RITA-MI project), followed (if successful) by a phase II clinical efficacy trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RITA-MI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RITA-MI" are provided by the European Opendata Portal: CORDIS opendata.